Articles tagged with Cancer Patients
A new blood test developed by RMIT University researchers could help personalize cancer treatments, making them safer and more effective. The test assesses how well different nanomedicines target cancer cells in the blood of leukemia patients, allowing for more tailored therapies.
A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.
Adding camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response in patients with early or locally advanced triple-negative breast cancer. The treatment showed substantial benefits, leading researchers to explore its potential as a neoadjuvant strategy.
Researchers at Osaka Metropolitan University developed a new technique for head and neck reconstruction that achieves 100% success rate in high-risk patients. The pedicled latissimus dorsi flap technique provides a reliable, fast, and minimally invasive option for complex tissue defects.
Researchers analyzed data from 11,797 adults with advanced solid cancers and found no difference in mortality rates during the shortage period. Prescription rates for cisplatin and carboplatin fell less than three percent overall, with alternative therapies helping mitigate the crisis.
A new study found that a low omega-6, high omega-3 diet with fish oil supplements significantly reduced prostate cancer cell proliferation in men. The findings suggest that dietary changes could potentially delay or prevent the need for more aggressive treatments.
A new study reveals that social risks like food insecurity and housing instability impede patients' ability to receive routine cancer screenings, even when they have access to healthcare. The research highlights the need for health providers to take a more holistic approach to patient care to address these challenges.
A study published in Journal of Pain and Symptom Management found that Reiki therapy resulted in clinically significant improvements in pain, fatigue, anxiety, nausea, and well-being among outpatients with cancer. The study involved 392 Reiki sessions for 268 unique patients, showing a mean improvement of 1.78 in pain and 2.09 in anxiety.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.
Researchers developed a deep learning model that classifies pancreatic cancer into molecular subtypes using histopathology images, achieving high accuracy and rapid turnaround time. The AI tool has the potential to improve patient outcomes by enabling timely and tailored treatment strategies.
The PATINA study demonstrates that palbociclib improves progression-free survival (PFS) in patients with HR+, HER2+ metastatic breast cancer, with a median PFS of 44.3 months. This represents an extension in median PFS of over 15 months compared to anti-HER2 therapy and endocrine therapy alone.
The PROSPECT-Lung trial evaluates the role of immunotherapy before and after surgery in resectable non-small cell lung cancer patients. The trial aims to determine whether adding immune checkpoint inhibitors to standard chemotherapy improves survival outcomes.
A new DNA sequencing test called AR-ctDETECT has been found to distinguish between patients with poor and favorable prognoses in advanced prostate cancer. The test identified circulating tumor DNA in 59% of patients and showed that detectable ctDNA was associated with worse overall survival.
The American College of Surgeons Geriatric Surgery Verification program significantly decreases hospital stays among older cancer patients, increasing their independence and likelihood of discharge home. The program addresses the unique needs of older adults undergoing major abdominal oncologic procedures.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
Researchers aim to improve treatment response in patients with clear cell renal cell carcinoma by reprogramming tumor cells into immune cells that recognize and kill cancer cells. This approach combines checkpoint inhibitors to enhance the immune response.
Researchers at UCLA Health presented several breakthroughs at the San Antonio Breast Cancer Symposium, including improved survival rates for advanced breast cancer patients who receive trastuzumab deruxtecan (T-DXd), a novel ADC. Additionally, new genomic testing and circulating tumor DNA analysis may help identify high-risk patients a...
A phase 3 trial shows that autologous stem cell transplants do not improve survival for mantle cell lymphoma patients in complete remission and undetectable minimal residual disease. Patients who remain MRD-positive after induction may benefit from ASCT, but longer follow-up is needed to confirm these findings.
A study suggests that low doses of the commonly prescribed hair loss treatment minoxidil are safe and effective for regrowing hair in most breast cancer patients. The researchers found that all participants who took a low dose of oral minoxidil saw improvements in hair growth or stabilization within three to six months.
Two clinical trials testing loncastuximab tesirine showed promising results in patients with high-risk forms of follicular lymphoma and marginal zone lymphoma. The treatment achieved impressive response rates, including a 70% complete response rate for marginal zone lymphoma and an overall response rate of 97% for follicular lymphoma.
Experts discuss strategies and best practices for sharing accurate, evidence-based health information with patients and caregivers. The event aimed to empower people with cancer to make informed choices about their care.
A team of UNC-Chapel Hill researchers will develop an oncology health learning system using AI-ready data to generate real-time identification of new cancer cases and support personalized treatments. The project aims to improve cancer diagnosis, care equity, and quality by creating accessible tools for health providers.
A phase 3 study demonstrated nearly 75% complete cancer remission in patients with high-risk bladder cancer unresponsive to BCG therapy. The novel treatment, cretostimogene grenadenorepvec, was well-tolerated and did not require bladder removal surgery.
A new ASTRO survey finds that prior authorization delays lead to treatment interruptions, hospitalizations, and patient deaths. The problem is worsening, with patients experiencing longer treatment delays than during the COVID-19 pandemic.
A new study has solved a years-old mystery about which patients with aggressive breast cancer are helped by a targeted cancer treatment. The researchers found that low levels of the protein IGFBP7 can predict which patients will benefit from the treatment, providing hope for its continued development.
A new clinical pathway aims to address the intense fear of cancer returning, empowering patients to regain confidence. The three-step plan involves assessment, diagnosis, and stepped-care support to tackle moderate to severe anxiety, which affects 60% of people living with or beyond cancer.
Researchers have found that B7-H4 helps ACC tumors evade the immune system, leading to poor survival outcomes. A new drug targeting B7-H4 showed promising results in shrinking tumors in aggressive cases.
A study found that postmenopausal women with low-risk tumors experience a long-term benefit from anti-hormonal treatment of at least 20 years, while younger women do not. The researchers highlight the need for new markers to predict long-term risk and benefit in younger patients.
Chronic fatigue syndrome patients' immune T cells become exhausted, a condition well-studied in cancer. Researchers now explore potential treatments to reverse this state, which may benefit ME/CFS patients.
A new chimeric antigen receptor T cell (CAR-T) therapy called obe-cel has delivered promising results in treating patients with an aggressive blood cancer. The treatment reduced immune toxicity and persisted for longer in patients, overcoming two common limitations of earlier CAR-T cell therapies.
The ESMO Asia Congress 2024 will focus on multidisciplinary oncology in the Asian region, featuring novel treatment modalities, management of specific cancer types and pan-Asian trials. Key highlights include insights into genetics, biology and practice differences between West and Asia.
Researchers found impaired PD-1 activity can significantly reduce antibody diversity and quality in memory B cells. This may explain the increased rates of infection reported in patients with cancer receiving checkpoint inhibitor therapy.
A new study has found that tamoxifen works better for some people due to their unique gut microbiota. Researchers discovered a specific enzyme, beta-glucuronidase, in certain bacteria that helps recycle the drug into its effective form. This finding may lead to tailored treatment interventions for breast cancer patients.
A study found that mindfulness training tailored to cancer patients' needs improved psychological well-being and self-confidence for advance care planning. For caregivers, it supported improvements in quality of life at follow-up. Mindfulness practices helped individuals address emotional barriers to advance care planning.
The Gustave Roussy Prize recognizes scientists whose work improves cancer treatment and patient outcomes. Established by Pierre Fabre Laboratories, the €200,000 award aims to push boundaries of oncology and offer personalized treatments.
The updated ASTRO guideline recommends personalized treatment approaches for patients with locally advanced rectal cancer, including non-surgical alternatives and intensified treatment regimens. The guideline aims to improve outcomes while preserving quality of life.
A new study suggests that a cancer peer support program called Stronger Together improved psychological outcomes, as well as overall quality of life, among patients with breast and gynecological cancers in Vietnam. The program showed promise for providing critical social support in low-resource settings.
A new study from UCLA Health Jonsson Comprehensive Cancer Center introduces a combined genetic and functional profiling approach to predict how glioblastoma will respond to therapy. The approach helps identify new ways to target and treat the tumors more effectively, including using an experimental drug called ABBV-155.
Among cancer survivors, male patients ages 15-39 have the highest rate of death by suicide. Suicide deaths increased three-fold in this age group between 2000 and 2021, with one in 65 deaths attributed to suicide in 2021.
Researchers found that sacubitril-valsartan, a commonly prescribed heart failure medication, can help prevent heart damage related to chemotherapy treatment among high-risk cancer patients. The study highlights the importance of identifying patients at high risk for heart damage and suggests strategies for early intervention.
Neuro-oncology experts developed guidelines to standardize AI use in brain cancer diagnosis and treatment. The recommendations aim to ensure reliable clinical trial results and protect patients.
A new study found that a remote telemedicine tool called SpotCheck is highly accurate in diagnosing melanoma, with experts able to remotely examine skin lesions using dermoscopy. The tool has the potential to address diagnostic and treatment disparities for lower-income populations with limited access to dermatologists.
A new combination of immunotherapy and epigenetic drug may transform resistant pancreatic tumors into susceptible ones, according to a study by Johns Hopkins Medicine researchers. The treatment showed promise in a subset of patients, with tumor shrinkage and durable responses observed over several months.
A Chinese Medical Journal study reveals that patients with prostate cancer can undergo surgical removal without a pre-operative biopsy, using a combination of mpMRI and PSMA PET/CT imaging. This approach reduces costs and complications associated with traditional biopsy methods.
Testicular cancer is a highly treatable condition with high survival rates when detected early, but patients with the highest-risk disease face a lower prognosis. New genetic changes have been identified using whole genome sequencing, offering potential new treatment strategies.
New treatment combinations and predictive biomarkers hold promise for improving bladder cancer outcomes. The NIAGARA trial showed that combining immune checkpoint inhibitors with chemotherapy can significantly increase two-year survival rates and reduce cancer recurrences.
Patients receiving MRI-guided SBRT experienced significantly fewer urinary and bowel side effects compared to CT-guided treatment. MRI guidance also correlated with improved scores on specific quality-of-life measures, including bowel function and sexual health.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
The new NCCN Guidelines for Patients: Quitting Smoking provide critical support and guidance for individuals with cancer seeking to quit smoking. The guidelines offer a fresh perspective and renewed hope, featuring multiple evidence-based options, including nicotine replacement therapy, behavior therapy, and non-nicotine medicines.
The new hospital will provide patient-centered care with personalized, compassionate treatment and groundbreaking research. Patients will have access to top specialists and pioneering therapies in cancer treatment.
Researchers created tiny lab-grown models of human immune systems to study immune function in cancer and predict disease treatment response. The miniature models support longer cell function, allowing processes like antibody formation to occur similar to the human body.
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
A recent study found that only half of young cancer patients report discussing fertility preservation options with their healthcare provider. The study, which included 473 patients between the ages of 18 and 49, highlights the need for comprehensive reproductive health care in oncology treatment. Fertility preservation discussions were...
A new real-world study found that Comprehensive Genomic Profiling (CGP) leads to better personalized treatment and patient outcomes when done early in a cancer diagnosis. CGP-assessed patients received biomarker-driven targeted therapy or immunotherapy, significantly improving overall survival of 25 months compared to chemotherapy alone.
A new clinical trial found that the addition of immunotherapy drug pembrolizumab to standard treatment improved disease-free survival rates for patients with stage 3 soft tissue sarcoma. The study showed that pembrolizumab reduced recurrence or death for patients by 15 percentage points compared to standard treatment.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
The Wyss Institute's iNodes team has been awarded an ARPA-H Sprint for Women's Health to develop implantable immune organs for treating ovarian cancer. The iNodes concept is based on the formation of lymphoid organs in tumors, which can be reprogrammed to attack cancer cells and retain a long-term immune memory.
A new study by Cedars-Sinai reveals that significant percentages of older men with intermediate- and high-risk prostate cancers are being subjected to aggressive treatments that may not extend their lives, highlighting the need for a more personalized approach to cancer treatment. The study suggests that better estimation, communicatio...
The VANCE trial demonstrates that Singapore has the expertise and capabilities to run large-scale global cell therapy trials. The study shows promising results for patients with recurrent or metastatic NPC treated with EBV-CTL therapy, with median survival rates of up to 29.9 months.
AI models trained on limited data may misdiagnose certain populations, particularly those in underserved communities. Researchers propose six key strategies to develop fair AI models, including using diverse datasets and transparent decision-making processes.